Thrombotic Events in Homozygotes with a Proven or Highly Probable Arg304Gln Factor VII Mutation (FVII Padua)1): Only Limited Replacement Therapy is Needed in Case of Surgery

Author(s): Antonio Girolami*, Elisabetta Cosi, Silvia Ferrari, Bruno Girolami, Maria L. Randi.

Journal Name: Cardiovascular & Hematological Disorders-Drug Targets
(Formerly Current Drug Targets - Cardiovascular & Hematological Disorders)

Volume 19 , Issue 3 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Objective: To investigate the prevalence of thrombotic events among patients with proven or highly probable homozygosis for the Arg304Gln (Factor VII Padua) defect or compound heterozygosis containing the Arg304Gln mutation.

Methods: Homozygotes and compound heterozygotes proven by molecular studies to have the Arg304Gln mutation were gathered from personal files and from two PubMed searches. In addition, patients with probable homozygosis on the basis of clotting tests (discrepancies among Factor VII activity levels according to the tissue thromboplastin used) were also gathered.

Results: 30 proven homozygotes and 17 probable ones were gathered together with 8 compound heterozygotes. In the latter use, the associated mutation was Cys135Arg (twice), Gly180Arg, Arg304Trp, Arg315Trp, His348Gln, Gly365Cys. The prevalence of venous thrombotic events was 16.6, 11.8 and 11.1 percent, respectively for the three groups of patients. Heterozygotes showed no thrombotic event. The difference for proven homozygotes was statistically significant, while for the other groups only a trend was present.

Conclusion: proven homozygous or compound heterozygous patients with the Arg304Gln mutation showed a higher than expected incidence of thrombotic events. The same is true for probable cases gathered only on the basis of clotting tests. These patients, because of their frequent lack of bleeding and for their relatively high prevalence of thrombosis should probably receive only limited replacement therapy in case of surgical procedures.

Keywords: Factor VII, deficiency, bleeding, thrombosis, mutation, sonography.

[1]
Perry, D.J. Factor VII Deficiency. Br. J. Haematol., 2002, 118, 689-700.
[2]
Mariani, G.; Herrmann, F.H.; Schulman, S.; Batorova, A.; Wulff, K.; Etro, D.; Dolce, A.; Auerswald, G.; Astermark, J.; Schved, J.F.; Ingerslev, J.; Bernardi, F. Thrombosis in inherited factor VII deficiency. J. Thromb. Haemost., 2003, 1, 2153-2158.
[3]
Girolami, A.; Fabris, F.; Dal Bo Zanon, R.; Ghiotto, G.; Burul, A. Factor VII Padua: A congenital coagulation disorder due to an abnormal factor VII with a peculiar activation pattern. J. Lab. Clin. Med., 1978, 91, 387-395.
[4]
Triplett, D.A.; Brandt, J.T.; Batard, M.A.; Dixon, J.L.; Fair, D.S. Hereditary factor VII deficiency: heterogeneity defined by combined functional and immunochemical analysis. Blood, 1985, 66, 1284-1287.
[5]
Wulff, K.; Herrmann, F.H. Twenty two novel mutations of the factor VII gene in factor VII deficiency. Hum. Mutat., 2000, 15, 489-496.
[6]
Girolami, A.; Candeo, N.; Bonamigo, E.; Fabris, F. Arg 304 Gln (FVII Padua) and Ala 294 Val mutations are equally present in patients with FVII deficiency and thrombosis. Eur. J. Haematol., 201l, 87, 92-94.
[7]
James, H.L.; Girolami, A.; Hubbard, J.G.; Kumar, A.; Fair, D.S. The dysfunction of coagulation factor VII Padua results from substitution of arginine-304 by glutamine. Biochim. Biophys. Acta, 1993, 1172, 301-305.
[8]
Giansily-Blaizot, M.; Aguilar-Martinez, P.; Biron-Andreani, C.; Jeanjean, P.; Igual, H.; Schved, J.F. Study Group of Factor Seven Deficiency. Analysis of the genotypes and phenotypes of 37 unrelated patients with inherited factor VII deficiency. Eur. J. Hum. Genet., 2001, 9, 105-112.
[9]
Fromovich-Amit, Y.; Zivelin, A.; Rosenberg, N.; Landau, M.; Rosa, J.P.; Seligsohn, U. Of four mutations in the factor VII gene in Tunisian patients, one novel mutation (Ser339Phe) in three unrelated families abrogates factor X activation. Blood Coagul. Fibrinolysis, 2005, 16, 369-374.
[10]
Kirkel, D.; Lin, T.W.; Fu, S.W.; Dlott, J.S.; Sahud, M.A.
McCaffrey, T.; Rickles, F.R. Asymptomatic factor VII deficiency: Gene analysis and structure-function relationships. Blood Coagul. Fibrinolysis, 2010, 21, 91-94.
[11]
Girolami, A.; Berti de Marinis, G.; Bonamigo, E.; Allemand, E. Worldwide diffusion of FVII Arg304Gln coagulation defect (FVII Padua). Eur. J. Haematol., 2011, 86, 135-139.
[12]
Marty, S.; Barro, C.; Chatelain, B.; Fimbel, B.; Tribout, B.; Reynaud, J.; Schved, J.F.; Giansily-Blaizot, M. The paradoxical association between inherited factor VII deficiency and venous thrombosis. Haemophilia, 2008, 14, 564-570.
[13]
Shurafa, M.S.; Kumar, A.; Fair, D.S.; James, H.L. The molecular defect in factor VII Detroit is due to substitution of Arg by Gln. FASEB J., 1993, 7, 115. (Abstract)
[14]
Jin, Y.; Wang, Y.; Hao, X.; Yang, L.; Xie, H.; Zhu, L.; Yu, F.; Yang, X.; Wang, M. Genetic analysis of a pedigree with hereditary coagulation factor vII deficiency. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2015, 32, 222-225.
[15]
Sabharwal, A.K.; Kuppuswamy, M.N.; Foster, D.C.; Wildgoose, P.; Fisher, L.; Birktoft, J.J. Factor VII deficiency (F VII Richmond, R304Q mutant) associated with thrombosis. Circulation, 1992, 86(Suppl.), 679. (Abstract).
[16]
Tahatahely, A.; Raanlod, S.; Baghaipour, M.; Enayat, M.; Ala, F.; Rasrager-Larc, G. Factor VII genotype and clinical profile in 6 Iranian patients with congenital FVII deficiency. J. Thromb. Haemost., 2007, 5(Suppl.), 1405. (Abstract).
[17]
Horellou, M.H.; Chalendard, J.; Juin, F.; Conard, J. Source of tissue factor leading to discrepant plasma FVII levels in eight FVII- deficient patients of African origin. J. Thromb. Haemost., 2007, 5(Suppl. 2) P-M-002
[18]
Peyvandi, F.; Jenkins, V.P.; Mannucci, P.M.; Billio, A.; Zeinali, S.; Perkins, S.J.; Perry, D.J. Molecular characterisation and three-dimensional structural analysis of mutations in 21 unrelated families with inherited factor VII deficiency. Thromb. Haemost., 2000, 84, 250-257.
[19]
Bernardi, F.; Liney, D.L.; Patracchini, P.; Gemmati, D.; Legnani, C.; Arcieri, P.; Pinotti, M.; Redaelli, R.; Ballerini, G.; Pemberton, S.; Wacey, A.I.; Mariani, G.; Tuddenham, E.G.; Marchetti, G. Molecular defects in CRM+ factor VII deficiencies: modelling of missense mutations in the catalytic domain of FVII. Br. J. Haematol., 1994, 86, 610-618.
[20]
Fromovich-Amit, Y.; Zivelin, A.; Rosenberg, N.; Tamary, H.; Landau, M.; Seligsohn, U. Characterization of mutations causing factor VII deficiency in 61 unrelated Israeli patients. J. Thromb. Haemost., 2004, 2, 1774-1781.
[21]
Girolami, A.; Sueldo, E.; Ferrari, S.; Guerrero, G.; Cosi, E.; Arias, M. Report of the second patient with a homozygous FVII Padua (Arg304Gln) defect in Northern Argentina. M.J. Case, 2018, 3, 036.
[22]
Matsushita, T.; Kojima, T.; Emi, N.; Takahashi, I.; Saito, H. Impaired human tissue factor-mediated activity in blood clotting factor VIINagoya (Arg304-->Trp). Evidence that a region in the catalytic domain of factor VII is important for the association with tissue factor. J. Biol. Chem., 1994, 269, 7355-7363.
[23]
Ding, Q.L.; Wang, H.L.; Wang, X.F.; Wang, M.S.; Fu, Q.H.; Wu, W.M.; Hu, Y.Q.; Wang, Z.Y. Inherited coagulation factor VII deficiency caused by double heterozygotic mutations Arg304Gln and Arg304Trp. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2003, 20, 279-283.
[24]
Girolami, A.; Tezza, F.; Scandellari, R.; Vettore, S.; Girolami, B. Associated prothrombotic conditions are probably responsible for the occurrence of thrombosis in almost all patients with congenital FVII deficiency. Critical review of the literature. J. Thromb. Thromb., 2010, 30, 172-178.
[25]
Girolami, A.; Bertozzi, I.; Rigoni, I.; Muzzolon, R.; Vettore, S. Congenital FVII deficiency and thrombotic events after replacement therapy. J. Thromb. Thromb., 2011, 32, 362-367.
[26]
Krauss, J.S.; Matthews, A.; Oliver, J.; Lightsey, A.; Jonah, M.H.; Pantazis, C.G. African-American factor VII-deficient variants in Georgia (FVII variants). Am. J. Hematol., 1994, 47, 239-241.
[27]
Pollak, E.S.; Russell, T.T.; Ptashkin, B.; Smith-Whitley, K.; Camire, R.M.; Bauer, K.A. Asymptomatic factor VII deficiency in African Americans. Am. J. Clin. Pathol., 2006, 126, 128-132.
[28]
Barnett, J.M.; Demel, K.C.; Mega, A.E.; Butera, J.N.; Sweeney, J.D. Lack of bleeding in patients with severe factor VII deficiency. Am. J. Hematol., 2005, 78, 134-137.
[29]
Alexander, B.; Goldstein, R.; Landwehr, G.; Cook, C.D. Congenital SPCA deficiency: A hitherto unrecognized coagulation defect with hemorrhage rectified by serum and serum fractions. J. Clin. Invest., 1951, 30, 596-608.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 3
Year: 2019
Page: [233 - 238]
Pages: 6
DOI: 10.2174/1871529X19666190308114842
Price: $58

Article Metrics

PDF: 25
HTML: 3

Special-new-year-discount